We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+15.32%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.07B
AUM Growth
+$118M
Cap. Flow
-$32.4M
Cap. Flow %
-3.02%
Top 10 Hldgs %
72.05%
Holding
37
New
3
Increased
23
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$24.1M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$20.8M
3
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$18.6M
4
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.2M
5
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$12.1M

Top Sells

Rank Stock Value
1
VPHM
VIROPHARMA INC
VPHM
+$125M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$42.8M
3
SVNT
SAVIENT PHARMACEUTICALS INC
SVNT
+$5.46M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$4.17M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYBX
1
DELISTED
CYBERONICS INC
CYBX
$128M 11.91%
1,951,581
+32,063
+2% +$1.94M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$124M 11.56%
1,095,428
+31,986
+3% +$2.88M
AUXL
3
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$101M 9.44%
4,883,879
+320,359
+7% +$6.04M
CBST
4
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$92M 8.58%
1,336,136
+321,525
+32% +$20.8M
ABMD
5
DELISTED
Abiomed Inc
ABMD
$71.9M 6.7%
2,687,347
+33,000
+1% +$815K
ITMN
6
DELISTED
INTERMUNE INC
ITMN
$56.3M 5.25%
3,819,606
+223,850
+6% +$3.09M
QCOR
7
DELISTED
QUESTCOR PHARMA INC
QCOR
$52.5M 4.9%
963,995
+307,998
+47% +$18.2M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.4B
$52.1M 4.86%
741,087
+176,800
+31% +$12M
STAA icon
9
STAAR Surgical
STAA
$1.21B
$52M 4.85%
3,214,253
+2,935
+0.1% +$39.3K
AMAG
10
DELISTED
AMAG Pharmaceuticals
AMAG
$42.8M 3.99%
1,761,332
+45,955
+3% +$1.08M
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$302M
$40.2M 3.75%
3,238,624
+330,310
+11% +$3.32M
KYTH
12
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$33.6M 3.14%
900,559
+581,446
+182% +$24.1M
ANAC
13
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$26.9M 2.51%
1,603,278
+3,100
+0.2% +$42.9K
ARIA
14
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$23.5M 2.19%
+3,441,324
New +$18.6M
SQNM
15
DELISTED
SEQUENOM INC NEW
SQNM
$22M 2.05%
9,394,627
+1,192,373
+15% +$2.83M
MNTA
16
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$20.5M 1.91%
1,157,276
+20,600
+2% +$346K
ALIM
17
DELISTED
Alimera Sciences
ALIM
$17.1M 1.59%
242,332
– –
RIGL icon
18
Rigel Pharmaceuticals
RIGL
$750M
$14.9M 1.39%
521,700
-108,266
-17% -$3.18M
VPHM
19
DELISTED
VIROPHARMA INC
VPHM
$14.5M 1.35%
290,916
-2,802,375
-91% -$125M
PRTA icon
20
Prothena Corp
PRTA
$450M
$14.3M 1.33%
537,418
+448,918
+507% +$11.3M
NPSP
21
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$13.3M 1.24%
+439,100
New +$12.1M
QLTI
22
DELISTED
QLT Inc
QLTI
$11.4M 1.07%
2,053,311
+900
+0% +$4.46K
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$11.3M 1.05%
+186,900
New +$10.2M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$9.42M 0.88%
4,008,576
-613,654
-13% -$1.35M
EXAS
25
DELISTED
Exact Sciences
EXAS
$9.23M 0.86%
785,776
+5,900
+0.8% +$67.7K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q4 2013 Portfolio in Review

As of Q4 2013, Palo Alto Investors held 37 positions worth $1.07B, up 12% from $954M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Palo Alto Investors withdrew a net $32.4M in Q4 2013, closing 3 positions and reducing 6 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $42.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 36% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Ariad Pharmaceuticals Inc worth $23.5M.

  • Palo Alto Investors's largest Q4 2013 buy was Ariad Pharmaceuticals Inc: 3,441,324 shares worth $23.5M.
  • Palo Alto Investors added most to KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2013, an estimated $24.1M increase.
  • Palo Alto Investors's biggest Q4 2013 reduction was VIROPHARMA INC, cutting an estimated $125M.
  • Palo Alto Investors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $42.8M.
  • Palo Alto Investors's ten largest holdings make up 72% of its $1.07B portfolio in Q4 2013.
  • Palo Alto Investors opened 3 new positions and closed 3 in Q4 2013.
  • Palo Alto Investors's portfolio value rose 12% quarter-over-quarter to $1.07B.

Based on Palo Alto Investors's 13F filing for Q4 2013, filed 13 Feb 2014.